Limits...
Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States

View Article: PubMed Central - PubMed

ABSTRACT

We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.

No MeSH data available.


Kaplan–Meier curve showing the proportion of patients successfully completing treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036918&req=5

CIW477F2: Kaplan–Meier curve showing the proportion of patients successfully completing treatment.


Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
Kaplan–Meier curve showing the proportion of patients successfully completing treatment.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036918&req=5

CIW477F2: Kaplan–Meier curve showing the proportion of patients successfully completing treatment.

View Article: PubMed Central - PubMed

ABSTRACT

We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.

No MeSH data available.